Eledon Pharmaceuticals (ELDN) Stock: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$2.49
0.06 (2.26%)
▲
5d:
-6.04%
30d:
-16.72%
90d:
-37.28%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ELDN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ELDN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $2.49, which is considered oversold relative to its 30-day fair value range of $2.57 to $3.09.
Technical Outlook: Technically, ELDN is in a strong downtrend. The price is currently testing key support at $2.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.00 (+261.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ELDN is in a strong downtrend. The price is currently testing key support at $2.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.00 (+261.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.57 -
$3.09
Company Quality Score
57/100
(HOLD)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 36th percentile)
- NEUTRAL: Mixed technical signals (58/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 261.4% below Wall St target ($9.00)
- NEUTRAL: Bottoming setup forming (58/100) — watch for confirmation
- CAUTION: 5-day price weakness (-6.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.57 -
$3.09
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.31
(12.6%)
Support & Resistance Levels
Support Level
$2.42
Resistance Level
$3.09
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.23
Wall Street Target
$9.00
(+261.4%)
Share & Embed Analysis
Last updated: October 03, 2026 3:38 AM ET
Data refreshes hourly during market hours. Next update: 4:38 AM
Data refreshes hourly during market hours. Next update: 4:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
